Good Practice Guide Medication Error Recording Coding .

2y ago
18 Views
2 Downloads
1.37 MB
42 Pages
Last View : 10d ago
Last Download : 2m ago
Upload by : Pierre Damon
Transcription

23 October 2015EMA/762563/2014Pharmacovigilance Risk Assessment Committee (PRAC)Good practice guide on recording, coding, reporting andassessment of medication errorsFinalDraft finalised by Project and Maintenance Group 1 of Member Statesand EMA pharmacovigilance governance structure5 December 2014Draft consulted with the European Commission’s Patient Safety Quality ofCare Working Group (PSQCWG)11 February 2015Draft agreed by Pharmacovigilance Risk Assessment Committee (PRAC)12 February 2015Draft agreed by the Implementation Group (IG) of Member States andEMA pharmacovigilance governance structure18 February 2015Draft circulated to the Committee for Human Medicinal Products (CHMP)and the Co-ordination group for Mutual recognition and Decentralisedprocedures – human( CMD-h)19 February 2015Draft agreed for public consultation by the European Risk ManagementStrategy Facilitation Group (ERMS-FG)17 March 2015Draft released for public consultation14 April 2015End of public consultation (deadline for comments)14 June 2015Revised draft agreed by Project and Maintenance Group 1 of MemberStates and EMA pharmacovigilance governance structure15 August 2015Draft consulted with CHMP Quality Working Party (QWP) and BiologicsWorking Party (BWP)4 September 2015Revised draft consulted with Committee for Human Medicinal Products(CHMP) and Co-ordination group for Mutual recognition andDecentralised procedures – human( CMD-h)4 September 2015Revised draft agreed by Pharmacovigilance Risk Assessment Committee(PRAC)30 Churchill Place Canary Wharf London E14 5EU United KingdomTelephone 44 (0)20 3660 6000 Facsimile 44 (0)20 3660 5555Send a question via our website www.ema.europa.eu/contact10 September 2015An agency of the European Union European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.

Revised draft agreed by the Implementation Group (IG) of MemberStates and EMA pharmacovigilance governance structureRevised draft consulted with the European Commission’s Patient SafetyQuality of Care Working Group (PSQCWG)14 September 20155 October 2015Revised draft endorsed by the European Risk Management StrategyFacilitation Group (ERMS-FG)12 October 2015Revised draft adopted by Heads of Medicines Agencies (HMA)23 October 2015Final guidance published (date of coming into effect)Keywords27 November 2015Medication errors, pharmacovigilance, good practice, ICSR reporting,intercepted error, potential error, adverse reaction, MedDRA coding, PSUR,RMP, patient safety;Good practice guide on recording, coding, reporting and assessment of medication errorsEMA/762563/2014Page 2/42

Good practice guide on recording, coding, reporting andassessment of medication errorsTable of contentsExecutive summary . 51. Introduction . 52. Scope. 53. Legal basis . 64. Definitions . 74.1. Adverse event . 84.2. Adverse reaction . 84.3. Medication error . 84.3.1. Medication errors and correlation with harm and preventability . 94.3.2. Classification of medication error reports . 94.3.3. Intercepted medication error (‘near miss’) . 104.3.4. Potential medication error . 104.4. Patient safety incident. 114.5. Root cause analysis . 115. Structure and processes . 125.1. Recording of medication error reports . 125.2. Coding medication error reports . 145.2.1. Coding with Medical Dictionary for Regulatory Activities (MedDRA) . 145.2.2. General coding principles and MedDRA term selection . 155.2.3. Concept descriptions relevant for coding medication errors . 155.2.4. Medicinal product unavailability versus medication error . 165.2.5. Accidental and occupational exposures versus medication error . 175.2.6. Off-label use versus medication error and misuse . 175.2.7. Overdose/underdose versus medication error . 175.2.8. Product quality issues versus medication errors . 185.2.9. Coding of medication errors in context of drug delivery devices . 185.2.10. Standardised MedDRA Query for medication errors . 185.3. Reporting requirements for medication errors associated with adverse reactions . 195.3.1. Medication errors related to (invented) names . 215.3.2. Medication error reporting as emerging safety issue. 215.4. Periodic reporting of medication errors without adverse reaction(s) . 215.5. Follow-up of medication error reports . 235.5.1. Parameters to follow up when reporting medication errors . 235.5.2. ICH E2B (R3) ‘Additional information on drug’ data element. 285.6. Rules of anonymisation of personal data . 285.6.1. Healthcare professional reporting . 29Good practice guide on recording, coding, reporting and assessment of medication errorsEMA/762563/2014Page 3/42

5.6.2. Potential liability aspects . 296. Operation of the EU regulatory network . 306.1. The role of competent authorities in EU Member States . 306.1.1. Collaboration with national patient safety organisations . 306.2. The role of the Agency’s Pharmacovigilance Risk Assessment Committee . 326.3. The role of healthcare professionals, patients and consumers . 326.4. The role of marketing authorisation holders . 33List of acronyms . 34Annexes . 35Annex 1 - Simplified reporting rules for medication errors associated with adverse reactionspost EudraVigilance audit . 35Annex 2 - Templates for summary tabulation and listing of individual cases of medicationerrors . 36Annex 3 - Additional coding examples for medication errors . 38Annex 4 - Business process proposal for using ICH E2B (R3) for recording medication errorsin ICSRs . 42Good practice guide on recording, coding, reporting and assessment of medication errorsEMA/762563/2014Page 4/42

Executive summaryThe European Union (EU) pharmacovigilance legislation has introduced a number of changes related tomedication errors which affect the operation of pharmacovigilance systems in EU Member States. Tosupport implementation of the new legal provisions amongst the stakeholders involved in thereporting, evaluation and prevention of medication errors the European Medicines Agency (EMA) wasmandated to develop in collaboration with the EU regulatory network specific guidance for medicationerrors, taking into account the recommendations of a stakeholder workshop held in London in 2013.This good practice guide is a key deliverable of the EU regulatory network’s medication error initiativeto improve reporting and learning from medication errors for the benefit of public health.1. IntroductionErrors associated with the use of medicinal products are a major public-health burden and may happenwhen patients receive healthcare services for preventive, diagnostic, curative or rehabilitativepurposes. It has been estimated that 18.7 - 56% of all adverse events that occur among hospitalisedpatients result from medication errors that would be preventable. Medication errors are thus a concernat all stages of health care delivery in European health care systems 1.Medication errors occur as unintended mistakes in the process of prescribing, storing, dispensing,preparing or administering medicinal products in clinical practice. If a medication error occurs with thesame pattern or at an unacceptable frequency, or if it results in serious harm for the patient, it isessential to understand the causes, contributing factors and clinical consequences of the error, as wellas possible mitigating actions and solutions which could prevent the error from happening again.2. ScopeThe scope of this good practice guide includes the recording, coding, reporting and assessment ofmedication errors with medicinal products associated with suspected adverse reaction(s) in everydaymedical practice. This guide is therefore relevant to EU pharmacovigilance obligations applicable tocompetent authorities in EU Member States, marketing authorisation holders and the Agency.The primary purpose is to support competent authorities in EU Member States, marketing authorisationholders and the Agency to comply with their pharmacovigilance obligations detailed in Title IX ofDirective 2001/83/EC and Regulation (EC) 726/2004, Chapter 3, Article 28 with regard to therecording, reporting and assessment of suspected adverse reactions (serious and non-serious)associated with an error in prescribing, storing, dispensing, preparing for administration oradministering a medicinal product for human use authorised in the EU, regardless of the route ofauthorisation or the legal status of the medicinal product.The recording, coding, reporting and assessment of events associated with intentional overdose,abuse, misuse, occupational exposure, off-label use and of medication errors occurring in the contextof clinical trials conducted in accordance with Regulation (EU) No 536/2014, repealing Directive2001/20/EC, are outside the scope of this guidance.EU good pharmacovigilance practices (GVP) require marketing authorisation holders to summariseinformation on medication errors regardless of whether they are associated with adverse reaction(s) inperiodic safety update reports (PSUR) and to reflect the current knowledge about the risk ofmedication errors in risk management plans (RMP) for the purpose of continuous benefit-risk1von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of theliterature. Wien Klin Wochenschr 2003; 115:407–415.Good practice guide on recording, coding, reporting and assessment of medication errorsEMA/762563/2014Page 5/42

evaluation of medicinal products. This guide therefore also provides recommendations for marketingauthorisation holders for recording, coding, reporting and assessment of medication errors brought totheir attention (e.g. through direct patient or healthcare professional reporting) which are notassociated with adverse reaction(s).The scope of this guide also includes coding of medication error reports based on the MedicalDictionary for Regulatory Activities (MedDRA) term selection recommendations in the context of EUpharmacovigilance obligations. Specific coding examples are provided in addition to the guidance of theMedDRA Term Selection Points to Consider (MTS:PTC) document.The guidance acknowledges the fundamental role of patient safety incident reporting systems (seechapter 4.4.) established in several EU Member States to enhance patient safety by learning frompotential failures of the healthcare system, including from medication errors which do not result inadverse reaction(s). However, the authorities, bodies, organisations and/or institutions responsible forpatient safety incident reporting in EU Member States are outside the remit of Directive 2001/83/ECand Regulation (EC) No 726/2004 and medication errors not associated with adverse reaction(s) arenot required to be reported as individual case safety reports (ICSR) in line with EU pharmacovigilanceobligations.In line with the provisions of Article 107a (5) of Directive 2001/83/EC one of the objectives of thisguidance is the establishment of good practice for sharing information on medication errors associatedwith adverse reaction(s) between national competent authorities responsible for pharmacovigilance ofmedicinal products and authorities, bodies, organisations and/or institutions responsible for patientsafety incident reporting and learning systems in EU Member States. A model of collaboration andexchange of information is introduced as an example for good practice. It acknowledges that EUMember States may use different models that best fit their national requirements for the exchange ofinformation on medication errors.3. Legal basisArticle 1(11) of Directive 2001/83/EC provides the definition of an adverse reaction (see chapter 4.2.)which covers noxious and unintended effects resulting not only from the authorised use of a medicinalproduct at normal doses, but also from medication errors and uses outside the terms of the marketingauthorisation, including misuse and abuse of a medicinal product.Recital (17) of Directive 2010/84/EC provides that Member States should operate a pharmacovigilancesystem to collect information that is useful for the monitoring of medicinal products, includinginformation on suspected adverse reactions arising from use of a medicinal product within the terms ofthe marketing authorisation as well as from use outside the terms of the marketing authorisation,including overdose, misuse, abuse and medication errors, and suspected adverse reactions associatedwith occupational exposure.Article 101(1) of Directive 2001/83/EC lays down EU Member States’ requirements to operate apharmacovigilance system for the fulfilment of their pharmacovigilance tasks and to collect informationon the risks of medicinal products as regards patients’ or public health. That information shall inparticular refer to adverse reactions in humans, arising from use of the medicinal product within theterms of the marketing authorisation as well as from use outside the terms of the marketingauthorisation, and to adverse reactions associated with occupational exposure. This includes suspectedadverse reactions arising from errors with human medicinal products.Article 107a (5) of Directive 2001/83/EC further requires EU Member States to ensure that reports ofsuspected adverse reactions arising from an error associated with the use of a medicinal product thatare brought to their attention are made available to the EudraVigilance database and to anyGood practice guide on recording, coding, reporting and assessment of medication errorsEMA/762563/2014Page 6/42

authorities, bodies, organisations and/or institutions, responsible for patient safety within that EUMember State. They shall also ensure that the authorities responsible for medicinal products withinthat Member State are informed of any suspected adverse reactions brought to the attention of anyother authority within that EU Member State. From a public health perspective, it is good practice thatcompetent authorities in EU Member States are also aware of adverse reactions associated withmedication errors which may have been reported to national patient safety organisations (PSO) or anyother authorities, bodies, organisations and/or institutions responsible for patient safety within that EUMember State. The provisions of Article 107a (5) of Directive 2001/83/EC recognise the broader remitof PSO to tackle medication errors by introducing appropriate changes to clinical practice, which isoutside the legal remit of competent authorities in EU Member States. From a regulatory perspectivelearning from medication incident reports associated with adverse reactions will strengthen themonitoring of the safety of authorised medicinal products.Article 107a (5) of the Directive further requires that suspected adverse reaction reports arising froman error shall be appropriately identified in the standard web-based structured forms for the reportingof suspected adverse reactions by healthcare professionals and patients referred to in Article 25 ofRegulation (EC) No 726/2004.Each marketing authorisation holder is responsible for submitting PSURs according to Article 107b ofDirective 2001/83/EC and Article 28 (2) of Regulation (EC) 726/2004. The legal basis for thesubmission of RMPs is provided in Article 8 (3) (iaa) of Directive 2001/83/EC requiring that theapplication for a marketing authorisation shall be accompanied by a risk management plan whichdescribes the risk management system for the concerned product.The European Commission Implementing Regulation (EU) No 520/2012 provides the format andcontent requirements for PSUR and RMP. Article 34 (1) requires that the PSUR shall be based on allavailable data which provides the legal basis for summary information on patterns of medication errorsand potential medication errors, even when not associated with adverse outcomes in line with GVPModule VII (Rev 1).The reporting of medication errors occurring in the context of clinical trials is outside the scope of thisguidance and will be addressed in the context of the implementation of Regulation (EU) No 536/2014on clinical trials on medicinal products for human use, repealing Directive 2001/20/EC, which laysdown the reporting requirements for adverse events and serious adverse events by the investigator tothe sponsor (Article 41) and the reporting requirements for suspected unexpected serious adversereactions by the sponsor to EudraVigilance (Article 42). Annex III of Regulation (EU) No 536/2014 onsafety reporting states that medication errors, pregnancies and use outside what is foreseen in theprotocol, including misuse and abuse of the product, shall be subject to the same obligation to reportas adverse reactions.4. DefinitionsThe definitions provided in Article 1 of Directive 2001/83/EC and GVP Annex 1 (Rev 3) should beapplied for the purpose of this guidance; of particular relevance for recording, coding, reporting andassessment activities are the definitions provided in GVP Module VI together with this chapter whichinclude general principles presented i

Good practice guide on recording, coding, reporting and assessment of medication errors . Final . Draft finalised by Project and Maintenance Group 1 of Member States and EMA pharmacovigilance governance structure . 5 December 2014 . Draft consulted with the European Commissio

Related Documents:

We can overcome these medication errors by educating physicians, nurses regarding the areas where medication errors are more prone to occur. Key words: Medication error, Prescribing error, Dispensing error, Administration error, Documentation error, Transcribing error, EPA (Electronic prior authorization), Near miss, Missed dose. INTRODUCTION

Min Longitude Error: -67.0877 meters Min Altitude Error: -108.8807 meters Mean Latitude Error: -0.0172 meters Mean Longitude Error: 0.0028 meters Mean Altitude Error: 0.0066 meters StdDevLatitude Error: 12.8611 meters StdDevLongitude Error: 10.2665 meters StdDevAltitude Error: 13.6646 meters Max Latitude Error: 11.7612 metersAuthor: Rafael Apaza, Michael Marsden

B.Known causes of medication errors include: confusing labeling and nomenclature, human and environmental factors and medication shortages C.Medication safety measures include barcoding, smart pumps, medication reconciliation and pharmacists D.Medication errors are the most common sentinel event reported. E.None of the above LEARNINGOBJECTIVES

a. Read medication administration plan b. Read label 4. Observe student prepare and take medication as per medication plan 5. Document as required or stated in plan a. By unlicensed school staff member b. By student RECORDING MEDICATION ADMINISTRATION 1. Use Medication Administration Daily Log (paper or computer) 2. Record in ink only if using .

!Additionally, ME were categorized according to „Good practice guide on recording, coding, reporting and assessment of medication errors”: !!medication errors associated with adverse reaction(s), !!medication errors without harm, !!intercepted medication

The NPSA have identified seven key actions to improve medication safety. These actions include: t Increased reporting and learning from medication incidents. t Implementation by NPSA of safer medication practice recommendations. t Improved staff skills and competence. t Minimization of d

and a voluntary Medication Error-reporting Form was developed to report medication errors MEs that had occurred in patients of either sex were included in the study, and the reporters were given the choice to remain anonymous. The analysis was carried out and discussed with HCPs to minimise the recurrence.

Medication Error: any time the right medication is not taken as prescribed. . Report the unpleasant side effect and ask the prescribing doctor if the individual can take the medication at a different . Ask the physician or pharmacist if the pill comes in a coated or capsule form, or if it can be taken with food such as yogurt, applesauce or .